Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium

被引:84
|
作者
Ioffe, OB [1 ]
Papadimitriou, JC [1 ]
Drachenberg, CB [1 ]
机构
[1] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA
关键词
cell death; endometrial adenocarcinoma; proliferative activity; oncogene expression; bcl-2;
D O I
10.1016/S0046-8177(98)90429-4
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: The various morphological groupings of endometrial pathology are often difficult to distinguish from each other. The endometrium is an actively proliferating tissue and there is an overlap in cell proliferation fraction (CPF) between benign proliferative endometrium (BPE) and endometrial carcinoma (EC). Apoptosis in benign cycling endometrium is related to the menstrual cycle. In this study we evaluated CPF, apoptosis, and oncogenes that relate to cell turnover (bcl-2, p53, and c-erbB-2) in the spectrum of endometrial pathology. Methods: We examined a total of 64 cases consisting of 10 cases of BPE, 18 cases of simple endometrial hyperplasia (SEH), 18 cases of complex hyperplasia (CEH; including eight cases with atypical hyperplasia), and 18 cases of EC, FIGO grade 1. CPF was measured by the mitotic index (hll) and by the percentage of Ki-67 positive nuclei (Ki-67 index). Apoptotic index (AI) was determined on hematoxylin and eosin sections. Results: MI was 2.48% in BPE, 0.65% in SEH, 0.6% in CEH, and 0.91% in EC (P < .00001). Ki-67 index was 38.44%, 16.4%, 23.25%, and 31.7% respectively (P < .00001). AI was 1.17%, 2.2%, 2.57%, and 3.31% respectively (P = .02). The AI/MI and Al/Ki-67 ratios were lowest in BPE and highest in SEH (P = .007). All cases of BPE, 84% of SEH cases, 77% of CEH cases, and 88% of EC cases displayed cytoplasmic and/or nuclear bcl-2 expression. Cytoplasmic bcl-2 expression increased from BPE to SEH, whereas it decreased in CEH and EC with emergence of only nuclear expression. Of the EC cases, 38.8% showed intense nuclear bcl-2 reactivity and a significantly higher Ki-67 index than cases with ectoplasmic expression (P = .01). No p53 or c-erbB-2 expression was seen in either BPE or EH. Of the EC cases, 50% were positive for p53 whereas 30% were positive for c-erbB-2. C-erbB-2-positive cases had a significantly higher Ki-67 index: and AI than negative cases (P = .02). Cases of EC with p53 expression also had significantly higher AI (P = .01). Conclusions: In actively proliferating tissues like endometrium, CPF does not correlate with progression to malignancy In contrast, AI and derived AI/CPF ratios are better indicators of progression. The expression of p53, c-erbB-2, and nuclear bcl-2 in EC correlate with higher cell turnover indices (CPI; and Al). Copyright (C) 1998 by W.B. Saunders Company.
引用
收藏
页码:1150 / 1159
页数:10
相关论文
共 50 条
  • [41] Apoptosis in transitional cell carcinoma of bladder and its relation to proliferation and expression of P53 and Bcl-2
    Amirghofran, Z
    Monabati, A
    Khezri, A
    Malek-Hosseini, Z
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2004, 10 (03) : 154 - 158
  • [42] Effects of zerumbone on proliferation and apoptosis of esophageal cancer cells and on P53 and Bcl-2 expression levels
    Ma, Shiyang
    Lei, Yali
    Zhang, Li
    Wang, Jinhai
    [J]. ONCOLOGY LETTERS, 2018, 16 (04) : 4379 - 4383
  • [43] EXPRESSION OF BCL-2, P53 AND C-MYC PROTEINS IN CHRONIC LYMPHOCYTIC-LEUKEMIA - CORRELATION WITH APOPTOSIS
    MENTZ, F
    BLANC, C
    MICHEL, A
    BINET, JL
    MERLEBERAL, H
    [J]. BLOOD, 1994, 84 (10) : A657 - A657
  • [44] SEROUS PAPILLARY ADENOCARCINOMA OF THE ENDOMETRIUM - AN IMMUNOHISTOCHEMICAL COMPARISON OF BCL-2 AND P53 EXPRESSION
    ZHENG, W
    CAO, P
    GODWIN, T
    KRAMER, EE
    [J]. LABORATORY INVESTIGATION, 1995, 72 (01) : A99 - A99
  • [45] Proliferative activity in breast carcinoma evaluated by BrdU and PCNA - Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein
    Moriki, T
    Takahashi, T
    Tanioka, F
    Yamane, T
    Hara, H
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 1995, 191 (11) : 1122 - 1132
  • [46] Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; No correlation with prognosis
    Hardwick, RH
    Barham, CP
    Ozua, P
    Newcomb, PV
    Savage, P
    Powell, R
    Rahamin, J
    Alderson, D
    [J]. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1997, 23 (01): : 30 - 35
  • [47] P53, Bcl-2 expression and cell proliferation in benign breast lesions
    DiMartino, L
    Benini, E
    Faranda, A
    DeMontis, B
    Murenu, G
    Ferreli, A
    Daidone, MG
    Silvestrtni, R
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 1996, 8 (06) : 1053 - 1057
  • [48] Apoptosis in human uterine leiomyomas and myometrium: lack of correlation with expression of the bcl-2 and p53 proteins
    Xuxia, W
    Blanck, A
    Olovsson, M
    Lindblom, B
    [J]. HUMAN REPRODUCTION, 1998, 13 : 102 - 103
  • [49] Estrogen and progesterone receptors, c-erbB-2, p53, and Bcl-2 in thirty-three invasive micropapillary breast carcinomas
    LunaMore, S
    delosSantos, F
    Breton, JJ
    Canadas, MA
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 1996, 192 (01) : 27 - 32
  • [50] The prognostic significance of c-erbB-2, p53 and bcl-2 immunoexpression in patients with epithelial ovarian cancer treated with paclitaxel and platinum
    Timotheadou, E.
    Malamou-Mitsi, V.
    Krikoni, O.
    Aravantinos, G.
    Karina, M.
    Vrettlou, E.
    Efstratiou, I.
    Fountzilas, G.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 273 - 273